Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: vestor who wrote (642)	3/10/1998 8:22:00 PM
From: Thure Meyer	Respond to of 1837

You mean if the FDA approves their product. The answer is I don't know. I plan to call the company sometime this week and ask, maybe investor relations can give me a clue. As to the bottom line, it could be quite significant. You should read post #630, go to dojo.ie and check out the Premarin article. E.g., if the market is worth 500million to 1billion and Duramed picks up only 10% the stock will fly. Also, I'm sure that marketing partners will be lining up at the door if they get approval, so that distribution, advertising, access to doctors, etc. won't be a problem. Nevertheless, this is speculation. Drug lobbies are powerful. Thure

To: vestor who wrote (642)	3/10/1998 8:28:00 PM
From: Shake-Man	Read Replies (1) \| Respond to of 1837

Premarin is the biggest selling drug in the U.S. With the majority of people on some form of HMO or prescription insurance, they will be "forced" to get the drug that is on the HMO's formulary. And as we all know, HMO's and insurance companies have one goal above all...save money. So if Parke Davis can convince HMO's and ins. companies to put their conj. estrogen product on formulary over Premarin for a lower price, then Parke Davis, Duramed, and we the stockholders can open up our pockets and let the money start pouring in. Now if the FDA would only hurry their butts up...